发明名称 |
ANTI-CCL2 ANTIBODIES FOR TREATMENT OF SCLERODERMA |
摘要 |
The present invention provides, among other things, improved anti-CCL2 antibodies characterized with high affinity, potency, tissue selectivity and/or epitope specificity, and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions based on an anti-CCL2 antibody having an affinity of 10−12 M or greater. |
申请公布号 |
US2015158942(A1) |
申请公布日期 |
2015.06.11 |
申请号 |
US201314403025 |
申请日期 |
2013.05.22 |
申请人 |
Shire Human Genetic Therapies, Inc. |
发明人 |
Martini Paolo G.V.;Natarajan Madhusudan;Haslett Patrick Anthony John;Seymour Albert Barnes |
分类号 |
C07K16/24 |
主分类号 |
C07K16/24 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating scleroderma comprising
administering to an individual who is suffering from or susceptible to scleroderma an effective amount of anti-CCL2 antibody, or fragment thereof, such that at least one symptom or feature of scleroderma in a target tissue is reduced in intensity, severity, or frequency, or has delayed onset. |
地址 |
Lexington MA US |